Ibogaine clinical trials
A working map of completed, active, and registry-listed research involving ibogaine, noribogaine, and related proprietary analogs—read with attention to trial design, monitoring, regulatory status, and what has not yet been published.
01 / The map
Ibogaine research sits across several different settings: academic protocols, industry programs developing analogs, and regulated studies that may rely on national research pathways. The ClinicalTrials.gov study registry is a useful starting point because it records listed indications, recruitment status, study design, estimated enrollment, and named outcome measures. A listed study is not, by itself, evidence that an intervention works.
For opioid use disorder, alcohol or stimulant use, PTSD, traumatic brain injury, and depression, records often differ substantially in their population, comparator, follow-up period, and setting. Some are single-dose studies with inpatient observation; others may assess repeated dosing or pair investigational dosing with psychotherapy. Our broader evidence-first ibogaine overview can help place these trial records alongside the wider safety and regulatory questions.
Labels matter. “Completed” may mean data collection ended, not that results are available. “Active, not recruiting” may mean follow-up or analysis continues. When no peer-reviewed results publication is identified, this page treats the entry as registry only. For compound context, including distinctions commonly made around how ibogaine works in the body, it is important not to infer clinical benefit from pharmacology alone.
02 / Study architecture
Phase and design give a trial its basic frame. Early studies frequently emphasize dose, tolerability, pharmacokinetics, electrocardiographic effects, and feasibility. Later controlled studies may specify abstinence-related outcomes, changes in use, symptom scales, retention, or functional measures as primary endpoints. Sample size should be read as a design feature—not as proof of effect—and small studies are generally less able to provide precise estimates.
Academic sponsors may investigate a question within a university or hospital research structure. Industry sponsors may evaluate a patented analog or formulation. Government involvement can appear through funding, oversight, or a public research setting. These categories describe a study’s structure, not its outcome.
OUD, alcohol or stimulant use, PTSD, TBI, and depression are not interchangeable study populations. Eligibility criteria, co-occurring medications, withdrawal management, and follow-up plans can change the meaning of a result.
Country and regulator affect how a study proceeds. “IND,” “compassionate use,” and marketing authorization are distinct concepts. The FDA’s explanation of an investigational new drug application makes clear that an IND is a pathway for clinical investigation, not a finding of safety or effectiveness for general use.
03 / Concrete proof wall
Ibogaine protocols commonly foreground cardiac risk assessment because QT interval changes and arrhythmia concerns can shape both eligibility and observation. The NCBI overview of long QT syndrome provides context for why QT-related screening is clinically significant, while a particular trial protocol supplies the details of what it actually does.
Screening. ECG. Electrolytes. Observation. Escalation plans.
Before dosingRecords may describe medical history review, medication exclusions, baseline ECGs, and laboratory assessment. The presence of a criterion does not establish that all risk can be removed.
During dosingInpatient cardiac monitoring, serial ECGs, telemetry, clinician observation, and prespecified stopping rules are design features worth checking directly in a protocol or registry entry.
After dosingFollow-up can address acute safety, psychiatric symptoms, substance-use measures, and adverse-event reporting. Its duration and completeness affect what can reasonably be concluded.
04 / Regulatory frame
FDA approval, European authorization, an investigational application, and compassionate-use access are not interchangeable. In the European Union, the European Medicines Agency’s clinical-trials framework describes a distinct research environment from a marketing authorization. A trial may be lawful in a particular jurisdiction without the compound being broadly approved as a medicine there.
Likewise, patient interest in research should be kept separate from commercial treatment claims. People comparing care settings may encounter information about ibogaine treatment centers in Canada or estimates of the cost of ibogaine treatment in Mexico; neither category substitutes for a registered protocol, participant screening, or trial-level safety procedures.
05 / Questions
It means a public trial record was identified, but no peer-reviewed results publication was identified for this overview. Registry entries can still help clarify the indication, sponsor type, location, enrollment target, endpoints, and monitoring plan; they should not be read as outcome evidence.
No. An IND can permit a clinical study to proceed under FDA oversight. It is not a marketing approval and does not establish that ibogaine, noribogaine, or an analog is safe or effective for a condition. The regulatory timeline offers a separate way to track those distinctions over time.
A proprietary analog may have a different chemical profile and development plan from ibogaine itself. Study populations can also differ by diagnosis, medication status, history, dose schedule, inpatient requirements, psychotherapy integration, and primary endpoint. A practical starting point for chemical terminology is an ibogaine HCl reference guide, followed by the individual protocol.
Begin with the official registry record, confirm the listed site and recruitment status, and discuss individual circumstances with qualified professionals. The safety and monitoring context is designed to make the protocol questions—especially cardiac screening, medication review, and observation—easier to recognize.
Working principle
Trial registries, published papers, and regulatory documents can show where a research program stands. They cannot replace individualized medical or legal guidance, and they should not be stretched into promises about outcomes.